Eagle Pharmaceuticals, Inc. (EGRX), which went public last month, has as many as six candidates in its pipeline in addition to two approved...
Lannett Company, Inc. (LCI) is cashing in on generic drugs as it recently reported record sales and gross margins. This Zacks Rank #1 (Strong Buy...
Enanta Pharmaceuticals, Inc. (ENTA) was a big mover last session with its shares rising over 13% on the day. The move came on solid volume too...
Galectin Therapeutics Inc.’s (GALT) carbohydrate-based galectin inhibitor GR-MD-02 is currently in phase I development for the treatment...
Avanir Pharmaceuticals, Inc. (AVNR) announced preliminary results for the first quarter of fiscal 2014 (year ending in Sep 2014) with gross...
In a bid to strengthen its position in pet therapeutics, Aratana Therapeutics, Inc. (PETX) recently announced that it has acquired Belgium-based...
RedHill Biopharma Ltd. (RDHL) currently does not have any approved product in its portfolio and is making efforts to invest in the development...
On Jan 2, 2014, Zacks Investment Research upgraded Gentium (GENT) to a Zacks Rank #1 (Strong Buy). Why the Upgrade? Shares of Gentium, an...
GlaxoSmithKline (GSK) announced that it has completed the divestment of its thrombosis brands, Arixtra and Fraxiparine and nutritional drinks...
Galectin Therapeutics, Inc. (GALT) was a big mover last session, as the company saw its shares rise over 13% on the day. The move came on solid...
Lannett Company, Inc. (NYSE MKT: LCI) today announced that the company will present at the Oppenheimer 24th Annual Healthcare Conference on...
Lannett Company, Inc. (NYSE MKT: LCI) today announced that it will transfer the listing of its common stock to the New York Stock Exchange...
IntelliPharmaCeutics International Inc. (IPCI) was a big mover last session, as the company saw its shares shoot by nearly 162% on the day. The...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.